Jiandao Biotechnology

Jiandao Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of next-generation antibody-drug conjugates (ADCs) and multi-specific antibodies for oncology. Founded by industry veterans with extensive experience at global firms like Genentech and Amgen, the company leverages its proprietary JD-Connect platform to engineer site-specific conjugation, aiming to enhance the stability and therapeutic window of its candidates. Its lead program, JD-1001, is a Claudin 18.2-targeted ADC currently in Phase 1 clinical trials for advanced solid tumors. Jiandao's pipeline also includes JD-1002, a Nectin-4-targeted ADC, and several earlier-stage programs targeting high-value oncology markers. The company is backed by prominent life science investors and is positioned as a rising player in the competitive Chinese ADC landscape.